Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020

核医学/放射性医薬品の世界市場

◆タイトル:Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020
◆商品コード:MAM-PH-3590
◆調査・発行会社:MarketsandMarkets
◆発行日:2015年7月7日
◆ページ数:193
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥638,450見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥751,450見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥920,950見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、核医学/放射性医薬品の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観、市場シェア分析、種類別分析、治療別分析、用途別分析、地域別分析、市場規模及び予測、競争状況、関連企業分析などの情報をお届けいたします。

Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015.

In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.

In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets for the manufacturers of radiopharmaceuticals.

The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings. These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the nuclear medicine/radiopharmaceuticals market. The report analyzes the nuclear medicine/radiopharmaceuticals market by type, and application, and procedural volume

• Product Development/Innovation: Detailed insights on the upcoming technologies, research and development activities, and new product launches in the nuclear medicine/radiopharmaceuticals market

• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine/radiopharmaceuticals technologies across regions

• Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the nuclear medicine/radiopharmaceuticals market

• Competitive Assessment: In-depth assessment of the market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine/radiopharmaceuticals market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21

2 RESEARCH METHODOLOGY 22
2.1 RESEARCH METHODOLOGY STEPS 22
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
2.2.1 SECONDARY RESEARCH 23
2.2.2 PRIMARY RESEARCH 24
2.2.3 KEY INDUSTRY INSIGHTS 24
2.3 KEY DATA FROM PRIMARY SOURCES 25
2.4 KEY INSIGHTS FROM PRIMARY SOURCES 26
2.5 MARKET SIZE ESTIMATION METHODOLOGY 26
2.6 RESEARCH DESIGN 28
2.7 MARKET DATA VALIDATION AND TRIANGULATION 29
2.8 ASSUMPTIONS FOR THE STUDY 29

3 EXECUTIVE SUMMARY 30
3.1 INTRODUCTION 30
3.2 CURRENT SCENARIO 31
3.3 FUTURE OUTLOOK 31
3.4 CONCLUSION 33
4 PREMIUM INSIGHTS 34
4.1 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 34
4.2 SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTICS MARKET, BY REGION AND APPLICATION 35
4.3 REGIONAL SNAPSHOT OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 36
4.4 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020) 37

5 MARKET OVERVIEW 38
5.1 INTRODUCTION 39
5.2 MARKET DYNAMICS 39
5.2.1 DRIVERS 40
5.2.1.1 Increasing preference for SPECT and PET scans 40
5.2.1.2 Advances in radiotracers 40
5.2.1.3 Alpha radio immunotherapy-based targeted cancer treatment 40
5.2.1.4 Increasing incidence of cancer and cardiac ailments 41
5.2.2 RESTRAINTS 42
5.2.2.1 Shorter half-life of radiopharmaceuticals restricts its usage 42
5.2.2.2 Stringent regulatory and GMP guidelines 42
5.2.2.3 Competition from conventional diagnostic procedures 43
5.2.3 OPPORTUNITIES 44
5.2.3.1 Potential radioisotopes in the pipeline 44
5.2.3.2 High demand in emerging markets 44
5.2.3.3 Neurological applications 44
5.2.4 THREAT 45
5.2.4.1 Shutdown of nuclear reactors 45

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 47
6.1 INTRODUCTION 48
6.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 50
6.2.1 SPECT RADIOPHARMACEUTICALS 52
6.2.1.1 Technetium-99m (Tc-99m) 53
6.2.1.2 Thallium-201 (Tl-201) 54
6.2.1.3 Gallium-67 (Ga-67) 55
6.2.1.4 Iodine (I-123) 56
6.2.1.5 Others 56
6.2.2 PET RADIOPHARMACEUTICALS 57
6.2.2.1 Fluorine-18 (F-18) 59
6.2.2.2 Rubidium-82 (Rb-82) 60
6.2.2.3 Others 60
6.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 61
6.3.1 BETA EMITTERS 63
6.3.1.1 Iodine-131 (I-131) 65
6.3.1.2 Yttrium-90 (Y-90) 66
6.3.1.3 Samarium-153 (Sm-153) 66
6.3.1.4 Rhenium-186 (Re-186) 67
6.3.1.5 Lutetium-177 (Lu-177) 68
6.3.1.6 Others 68
6.3.2 ALPHA EMITTERS 69
6.3.2.1 Radium-223 (Ra-223) 70
6.3.3 BRACHYTHERAPY 71
6.3.3.1 Iodine-125 72
6.3.3.2 Iridium-192 73
6.3.3.3 Palladium-103 74
6.3.3.4 Cesium-131 74
6.3.3.5 Others 75

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME 76
7.1 INTRODUCTION 77
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 78
7.2.1 SPECT RADIOPHARMACEUTICALS 79
7.2.2 PET RADIOPHARMACEUTICALS 80
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 81
7.3.1 BETA EMITTERS 82
7.3.2 ALPHA EMITTERS 83
7.3.3 BRACHYTHERAPY 84

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 85
8.1 INTRODUCTION 86
8.2 DIAGNOSTIC APPLICATIONS 86
8.2.1 SPECT APPLICATIONS 86
8.2.1.1 Cardiology 89
8.2.1.2 Lymphoma 89
8.2.1.3 Neurology 91
8.2.1.4 Thyroid 92
8.2.1.5 Other Diagnostic Applications 93
8.2.2 PET APPLICATIONS 93
8.2.2.1 Oncology 96
8.2.2.2 Cardiology 96
8.2.2.3 Neurology 97
8.2.2.4 Other PET Applications 98
8.3 THERAPEUTIC APPLICATIONS 99
8.3.1 THYROID 101
8.3.2 BONE METASTASIS 102
8.3.3 LYMPHOMA 103
8.3.4 ENDOCRINE TUMORS 104
8.3.5 OTHER THERAPEUTIC APPLICATIONS 104

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION 106
9.1 INTRODUCTION 107
9.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 108
9.2.1 NORTH AMERICA 109
9.2.1.1 DEVELOPMENT OF MO-99 PRODUCTION FACILITIES IN THE U.S. 110
9.2.1.2 FDA APPROVALS OF NEW RADIOPHARMACEUTICALS 110
9.2.1.3 EXTENSION OF OPERATIONS IN THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR 110
9.2.1.4 DEVELOPMENT OF ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA 110
9.2.2 EUROPE 113
9.2.2.1 INCREASING ACCEPTABILITY OF 18F-FDG PET-CT IN THE U.K. 114
9.2.2.2 SHUTDOWN OF FRENCH NUCLEAR REACTOR 114
9.2.2.3 NEW IRRADIATION FACILITY IN GERMANY 115
9.2.3 ASIA-PACIFIC 118
9.2.3.1 INTRODUCTION OF NEW COST-EFFECTIVE TC-99 GENERATORS IN INDIA 119
9.2.3.2 HIGH INCIDENCE OF CANCER AND CARDIOVASCULAR DISEASE IN CHINA 119
9.2.3.3 INCREASING MO-99 PRODUCTION IN AUSTRALIA 119
9.2.3.4 INITIATIVES TO PROMOTE HEALTH IN ASIA-PACIFIC 119
9.2.4 REST OF THE WORLD 123
9.2.4.1 DEVELOPMENT OF MULTIPURPOSE RESEARCH REACTOR IN BRAZIL 124
9.2.4.2 ARGENTINA’S INCREASING IRRADIATION CAPACITY 124
9.2.4.3 CONVERSION OF THE SAFARI 1 REACTOR, FROM HEU-BASED MO-99 PRODUCTION TO LEU 124
9.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 127
9.3.1 NORTH AMERICA 127
9.3.1.1 FDA approval for alpha emitters in the U.S. 128
9.3.1.2 Therapeutic nuclear medicine, an alternative choice of treatment in oncology 129
9.3.1.3 Increase in the incidence of thyroid cancer 129
9.3.1.4 Expertise in isotope production 129
9.3.1.5 Government initiatives 129
9.3.1.6 High incidence of cancer 130
9.3.2 EUROPE 132
9.3.2.1 Increasing awareness of radioisotope therapy in the U.K. 133
9.3.2.2 Adverse reactions to radiopharmaceuticals in France 133
9.3.2.3 Radionuklidtherapeutika—research program conducted in Germany 134
9.3.2.4 Russia, an upcoming country for radionuclide therapy 134
9.3.3 ASIA-PACIFIC 136
9.3.3.1 Increased production of radiopharmaceuticals for therapeutic purposes in India 138
9.3.3.2 Aging population and increasing cancer incidence 138
9.3.3.3 Approval of radium (223Ra) dichloride by the therapeutic goods administration (TGA) 138
9.3.4 REST OF THE WORLD(ROW) 141
9.3.4.1 Growing aging population 141
9.3.4.2 Increase in cancer incidences 141

10 COMPETITIVE LANDSCAPE 144
10.1 OVERVIEW 144
10.2 MARKET SHARE ANALYSIS 144
10.2.1 INTRODUCTION 144
10.2.2 CARDINAL HEALTH, INC. 145
10.2.3 MALLINCKRODT PLC 146
10.2.4 GE HEALTHCARE 147
10.2.5 LANTHEUS MEDICAL IMAGING, INC. 148
10.2.6 BAYER HEALTHCARE 149
10.3 COMPETITIVE SITUATION AND TRENDS 151
10.3.1 INTRODUCTION 151
10.3.2 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS 152
10.3.3 ACQUISITIONS 153
10.3.4 MARKET DEVELOPMENT 154
10.3.5 EXPANSION 154
10.3.6 NEW PRODUCT LAUNCHES 155
10.3.7 OTHERS 156

11 COMPANY PROFILES 157
11.1 INTRODUCTION 157
11.2 CARDINAL HEALTH, INC. 158
11.2.1 BUSINESS OVERVIEW 158
11.2.2 PRODUCTS AND SERVICES 159
11.2.3 RECENT DEVELOPMENTS 159
11.2.4 MNM VIEW 160
11.3 MALLINCKRODT PLC 161
11.3.1 BUSINESS OVERVIEW 161
11.3.2 PRODUCT OFFERINGS 162
11.3.3 RECENT DEVELOPMENTS 162
11.3.4 MNM VIEW 162
11.4 GE HEALTHCARE 163
11.4.1 BUSINESS OVERVIEW 163
11.4.2 PRODUCT PORTFOLIO 164
11.4.3 RECENT DEVELOPMENTS 164
11.4.4 MNM VIEW 165
11.5 LANTHEUS MEDICAL IMAGING, INC. 166
11.5.1 BUSINESS OVERVIEW 166
11.5.2 PRODUCT OFFERINGS 167
11.5.3 RECENT DEVELOPMENTS 167
11.5.4 MNM VIEW 167
11.6 BAYER HEALTHCARE 168
11.6.1 BUSINESS OVERVIEW 168
11.6.2 PRODUCT OFFERINGS 169
11.6.3 RECENT DEVELOPMENTS 169
11.6.4 MNM VIEW 169
11.7 BRACCO IMAGING S.P.A 170
11.7.1 BUSINESS OVERVIEW 170
11.7.2 PRODUCT OFFERINGS 171
11.7.3 RECENT DEVELOPMENTS 171
11.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS 172
11.8.1 BUSINESS OVERVIEW 172
11.8.2 PRODUCTS AND SERVICES 172
11.8.3 RECENT DEVELOPMENTS 173
11.9 NORDION, INC. 174
11.9.1 BUSINESS OVERVIEW 174
11.9.2 PRODUCT OFFERINGS 175
11.9.3 RECENT DEVELOPMENTS 175
11.10 ADVANCED ACCELERATOR APPLICATIONS S.A. 176
11.10.1 BUSINESS OVERVIEW 176
11.10.2 PRODUCT OFFERINGS 177
11.10.3 RECENT DEVELOPMENTS 177
11.11 IBA MOLECULAR IMAGING 178
11.11.1 BUSINESS OVERVIEW 178
11.11.2 PRODUCT OFFERINGS 178
11.11.1 RECENT DEVELOPMENTS 179

12 APPENDIX 180
12.1 DISCUSSION GUIDE 180
12.2 COMPANY DEVELOPMENTS (2012–2015) 188
12.2.1 CARDINAL HEALTH, INC. 188
12.2.2 BAYER HEALTHCARE 188
12.3 AVAILABLE CUSTOMIZATIONS 189
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 189
12.5 RELATED REPORTS 190

LIST OF TABLES

TABLE 1 ALPHA RADIO IMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT TO BOOST THE GROWTH OF THE NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 41
TABLE 2 SHORTER HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING THE GROWTH OF THE NUCLEAR MEDICINE MARKET 43
TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE OFFER SIGNIFICANT GROWTH OPPORTUNITIES FOR THE NUCLEAR MEDICINE MARKET 45
TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET 46
TABLE 5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 49
TABLE 6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC SEGMENT, BY REGION, 2013-2020 ($MILLION) 50
TABLE 7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR DIAGNOSTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 51
TABLE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT ISOTOPES, BY REGION, 2013-2020 ($MILLION) 52
TABLE 9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR SPECT, BY ISOTOPE TYPE, 2013-2020 ($MILLION) 53
TABLE 10 GLOBAL SPECT MARKET SIZE FOR TECHNETIUM-99M ISOTOPES, BY REGION, 2013-2020 ($MILLION) 54
TABLE 11 GLOBAL SPECT MARKET SIZE FOR THALLIUM-201 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 54
TABLE 12 GLOBAL SPECT MARKET SIZE FOR GALLIUM-67 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 55
TABLE 13 GLOBAL SPECT MARKET SIZE FOR IODINE-123 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 56
TABLE 14 GLOBAL SPECT MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 57
TABLE 15 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET ISOTOPES, BY REGION, 2013-2020 ($MILLION) 58
TABLE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET, BY ISOTOPE, 2013-2020 ($MILLION) 58
TABLE 17 GLOBAL PET MARKET SIZE FOR FLUORINE-18 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 59
TABLE 18 GLOBAL PET MARKET SIZE FOR RUBIDIUM-82 ISOTOPES, BY REGION,
2013-2020 ($MILLION) 60
TABLE 19 GLOBAL PET ISOTOPES MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 61
TABLE 20 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY REGION, 2013-2020 ($MILLION) 62
TABLE 21 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC ISOTOPES, BY TYPE, 2013-2020 ($MILLION) 62
TABLE 22 GLOBAL BETA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 64
TABLE 23 GLOBAL BETA EMITTERS MARKET SIZE, BY ISOTOPE, 2013-2020 ($MILLION) 64
TABLE 24 GLOBAL BETA EMITTERS MARKET SIZE FOR IODINE-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 65
TABLE 25 GLOBAL BETA EMITTERS MARKET SIZE FOR YTTRIUM-90 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 66
TABLE 26 GLOBAL BETA EMITTERS MARKET SIZE FOR SAMARIUM-153 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 67
TABLE 27 GLOBAL BETA EMITTERS MARKET SIZE FOR RHENIUM-186 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 67
TABLE 28 GLOBAL BETA EMITTERS MARKET SIZE FOR LUTETIUM-177 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 68
TABLE 29 GLOBAL BETA EMITTERS MARKET SIZE FOR OTHER ISOTOPES, BY REGION,
2013-2020 ($MILLION) 69
TABLE 30 GLOBAL ALPHA EMITTERS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 70
TABLE 31 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY REGION, 2013-2020 ($MILLION) 72
TABLE 32 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BRACHYTHERAPY, BY ISOTOPES, 2013-2020 ($MILLION) 72
TABLE 33 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IODINE-125 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 73
TABLE 34 GLOBAL BRACHYTHERAPY MARKET SIZE FOR IRIDIUM-192 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 73
TABLE 35 GLOBAL BRACHYTHERAPY MARKET SIZE FOR PALLADIUM-103 ISOTOPES,
BY REGION, 2013-2020 ($MILLION) 74
TABLE 36 GLOBAL BRACHYTHERAPY MARKET SIZE FOR CESIUM-131 ISOTOPES, BY REGION, 2013-2020 ($MILLION) 75
TABLE 37 GLOBAL BRACHYTHERAPY MARKET SIZE FOR OTHER ISOTOPES, BY REGION, 2013-2020 ($MILLION) 75
TABLE 38 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE,
BY REGION, 2013–2020 (THOUSAND) 77
TABLE 39 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 78
TABLE 40 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 78
TABLE 41 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 79
TABLE 42 NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 79
TABLE 43 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 80
TABLE 44 NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 80
TABLE 45 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 81
TABLE 46 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 81
TABLE 47 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY TYPE,
2013–2020 (THOUSAND) 82
TABLE 48 NUCLEAR MEDICINE BETA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 82
TABLE 49 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 83
TABLE 50 NUCLEAR MEDICINE ALPHA EMITTERS PROCEDURE MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 83
TABLE 51 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY TYPE, 2013–2020 (THOUSAND) 84
TABLE 52 NUCLEAR MEDICINE BRACHYTHERAPY PROCEDURES MARKET SIZE, BY REGION, 2013–2020 (THOUSAND) 84
TABLE 53 SEGMENTATION OF NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR SPECT APPLICATIONS, BY TYPE 87
TABLE 54 NUCLEAR MEDICINE/RADIOPHAMACEUTICALS MARKET SIZE FOR SPECT APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 88
TABLE 55 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 89
TABLE 56 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 90
TABLE 57 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 91
TABLE 58 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 92
TABLE 59 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 93
TABLE 60 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION OF PET, BY APPLICATION 94
TABLE 61 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 ($MILLION) 95
TABLE 62 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 96
TABLE 63 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 97
TABLE 64 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 98
TABLE 65 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 98
TABLE 66 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013–2020($MILLION) 100
TABLE 67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 102
TABLE 68 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 103
TABLE 69 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 103
TABLE 70 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE TUMOR THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 104
TABLE 71 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2013–2020 ($MILLION) 105
TABLE 72 GLOBAL NUCLEAR MEDICINE /RADIOPHARMACEUTICALS MARKET SIZE, BY REGION, 2013-2020 ($MILLION) 107
TABLE 73 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
TABLE 74 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 111
TABLE 75 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 112
TABLE 76 NORTH AMERICA: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 112
TABLE 77 NORTH AMERICA: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 113
TABLE 78 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 115
TABLE 79 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 115
TABLE 80 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 116
TABLE 81 EUROPE: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 116
TABLE 82 EUROPE: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 117
TABLE 83 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 120
TABLE 84 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 120
TABLE 85 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 121
TABLE 86 ASIA-PACIFIC: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 121
TABLE 87 ASIA-PACIFIC: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 122
TABLE 88 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 124
TABLE 89 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 ($MILLION) 125
TABLE 90 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 125
TABLE 91 ROW: NUCLEAR MEDICINE SPECT RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 126
TABLE 92 ROW: NUCLEAR MEDICINE PET RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 ($MILLION) 126
TABLE 93 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 130
TABLE 94 NORTH AMERICA: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 131
TABLE 95 NORTH AMERICA: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE,
BY TYPE, 2013–2020 ($MILLION) 131
TABLE 96 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 132
TABLE 97 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 134
TABLE 98 EUROPE: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE,
2013–2020 ($MILLION) 135
TABLE 99 EUROPE: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE,
2013–2020 ($MILLION) 135
TABLE 100 EUROPE: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 136
TABLE 101 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 139
TABLE 102 ASIA-PACIFIC: NUCLEAR MEDICINE BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 139
TABLE 103 ASIA-PACIFIC: NUCLEAR MEDICINE BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 140
TABLE 104 ASIA-PACIFIC: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013–2020 ($MILLION) 140
TABLE 105 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY TYPE, 2013-2020 ($MILLION) 141
TABLE 106 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BETA EMITTERS MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 142
TABLE 107 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL BRACHYTHERAPY MARKET SIZE, BY TYPE, 2013–2020 ($MILLION) 142
TABLE 108 ROW: NUCLEAR MEDICINE/RADIOPHARMACEUTICAL THERAPEUTIC MARKET SIZE, BY APPLICATION, 2013-2020 ($MILLION) 143

LIST OF FIGURES

FIGURE 1 NUCLEAR MEDICINE/RADIOPHARMACEUTICAL MARKET SEGMENTATION 20
FIGURE 2 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS 22
FIGURE 3 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 25
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 27
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 27
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
FIGURE 7 DIAGNOSTICS MARKET TO WITNESS HIGHEST GROWTH RATE FROM
2015 TO 2020 30
FIGURE 8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015–2020 31
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET 32
FIGURE 10 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS,
2015–2020 33
FIGURE 11 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH 34
FIGURE 12 NORTH AMERICA DOMINATES THE SPECT NUCLEAR MEDICINE DIAGNOSTICS MARKET IN 2015 35
FIGURE 13 ASIA-PACIFIC TO WITNESS HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 36
FIGURE 14 DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD 37
FIGURE 15 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, CHALLENGES, & OPPORTUNITIES 39
FIGURE 16 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 48
FIGURE 17 THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.5% 49
FIGURE 18 PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.7% DURING THE
FORECAST PERIOD 51
FIGURE 19 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 17.3% DURING THE FORECAST PERIOD 63
FIGURE 20 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 9.4% DURING THE FORECAST PERIOD 87
FIGURE 21 THE NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 8.4% DURING THE FORECAST PERIOD 88
FIGURE 22 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 13.1% DURING THE FORECAST PERIOD 94
FIGURE 23 THE NEUROLOGY APPLICATION SEGMENT IS PROJECTED TO GROW AT THE HIGHEST CAGR OF 12.9% DURING THE FORECAST PERIOD 95
FIGURE 24 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC APPLICATIONS MARKET SEGMENTATION, BY TYPE 99
FIGURE 25 ASIA-PACIFIC TO GROW AT THE HIGHEST CAGR OF 12.2% DURING THE FORECAST PERIOD 100
FIGURE 26 THE ENDOCRINE TUMORS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD 101
FIGURE 27 NORTH AMERICA COMMANDS LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE DIAGNOSTIC MARKET IN 2015 108
FIGURE 28 NORTH AMERICA IS LIKELY TO WITNESS A CAGR OF 8.1% DURING THE FORECAST PERIOD 109
FIGURE 29 EUROPEAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET TO GROW AT A CAGR OF 7.7% DURING THE FORECAST PERIOD 114
FIGURE 30 ASIA-PACIFIC IS LIKELY TO WITNESS A CAGR OF 10.1% DURING THE FORECAST PERIOD 118
FIGURE 31 ROW NUCLEAR MEDICINE/RADIOPHARMACEUTICALS DIAGNOSTIC MARKET IS LIKELY TO GROW AT A CAGR OF 9% IN THE FORCAST PERIOD 123
FIGURE 32 NORTH AMERICA IS EXPECTED TO COMMAND THE LARGEST SHARE OF THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET IN 2015 127
FIGURE 33 NORTH AMERICA TO WITNESS A CAGR OF 10% IN THE GLOBAL NUCLEAR MEDICINE THERAPEUTIC MARKET DURING THE FORECAST PERIOD 128
FIGURE 34 EUROPE IS LIKELY TO WITNESS A CAGR OF 9.8% DURING THE FORECAST PERIOD 133
FIGURE 35 ASIA-PACIFIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTIC MARKET TO GROW AT A CAGR OF 12.2% DURING THE FORECAST PERIOD 137
FIGURE 36 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014 144
FIGURE 37 STRATEGIES ADOPTED BY KEY PLAYERS OVER THE LAST THREE YEARS
(2012-2015) 151
FIGURE 38 BATTLE FOR MARKET SHARE: AGREEMENTS/CONTRACTS/PARTNERSHIPS WAS THE KEY STRATEGY (2012 -2015) 152
FIGURE 39 AGREEMENTS, CONTRACTS, AND PARTNERSHIPS, 2012-2015 153
FIGURE 40 ACQUISITIONS, 2012-2015 153
FIGURE 41 MARKET DEVELOPMENT, 2012-2015 154
FIGURE 42 EXPANSIONS, 2012-2015 155
FIGURE 43 NEW PRODUCT LAUNCHES, 2012-2015 155
FIGURE 44 OTHER STRATEGIES, 2012-2015 156
FIGURE 45 GEOGRAPHICAL REVENUE MIX OF KEY PLAYERS IN THE MARKET 157
FIGURE 46 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT 158
FIGURE 47 MALLINCKRODT PLC: COMPANY SNAPSHOT 161
FIGURE 48 GE HEALTHCARE: COMPANY SNAPSHOT 163
FIGURE 49 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT 166
FIGURE 50 BAYER HEALTHCARE: COMPANY SNAPSHOT 168
FIGURE 51 NORDION, INC.: COMPANY SNAPSHOT 174
FIGURE 52 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT 176



【レポートのキーワード】

核医学、放射性医薬品、診断、治療、SPECT装置、PET装置、ベータ放射体、アルファ放射体、小線源療法

★調査レポート[核医学/放射性医薬品の世界市場] ( Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020 / MAM-PH-3590) 販売に関する免責事項
[核医学/放射性医薬品の世界市場] ( Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020 / MAM-PH-3590) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆